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Abstract
Background: Bleeding assessment tools (BATs) have been widely implemented in the 
evaluation of patients with suspected bleeding disorders. However, diagnostic BAT 
utility regarding platelet function disorders is still elusive.
Aim: We aimed to assess the diagnostic value of the International Society on 
Thrombosis and Haemostasis BAT (ISTH-BAT) for platelet function disorders in clini-
cal practice.
Methods: The clinical characteristics and laboratory data of all consecutive patients 
with a suspected bleeding disorder referred between January 2012 and March 2017 
to an outpatient unit of a university hospital were prospectively collected. The diag-
nostic evaluation was performed according to current recommendations following a 
prespecified protocol and platelet function was tested using light transmission ag-
gregometry as well as flow cytometry.
Results: Five hundred and fifty-five patients were assessed; 66.9% were female, 
median age was 43.7 years (interquartile range [IQR] 29.3, 61.7). Confirmed plate-
let function disorder was diagnosed in 54 patients (9.7%), possible platelet function 
disorder in 64 patients (11.5%), and other disorders in 170 patients (30.6%). Median 
scoring of the ISTH-BAT was 2 in patients without a bleeding disorder (IQR 1, 3), 4 
in patients with a possible platelet function disorder (2, 7), and 7 in patients with 
confirmed platelet function disorder (5, 9). Area under the receiver operating charac-
teristic curve (the area under the curve [AUC]) was 0.75 (95% CI 0.70, 0.80).
Conclusions: Presence of a platelet function disorder was associated with substan-
tially higher BAT scorings compared to patients without. Our data suggest that the 
ISTH-BAT provides a useful screening tool for patients with suspected platelet func-
tion disorders.
K E Y W O R D S
blood platelet disorders/diagnosis, hemorrhagic disorders/diagnosis, platelet function tests, 
predictive value of tests, prognosis, surveys and questionnaires
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1  | INTRODUC TION
Platelet function disorders (PFDs) are among the most common he-
reditary bleeding disorders, exposing affected patients to the risk 
of bleeding, particularly in the context of trauma and medical inter-
ventions.1,2 Diagnosing PFD is, however, cumbersome, and many 
patients are probably not identified.3 While severe PFD such as 
Glanzmann thrombasthenia, Bernard-Soulier syndrome, or syndro-
mic disorders are easier to recognize, diagnosis is much more elusive 
in the majority of PFD patients. The diagnostic evaluation requires 
laboratory assays that are technically challenging, time-consuming, 
and difficult to interpret.4 These tests tend also to be available in 
specialized laboratories only.3 In addition, complex preanalytic re-
quirements often necessitate blood drawing on site at the labora-
tory rather than having the sample shipped from farther afield.5,6 It 
is therefore important to select the patients for referral adequately.
Structured BATs such as from the International Society on 
Thrombosis and Haemostasis (ISTH-BAT) may be utilized as a 
screening instrument in specific patients and implemented in the 
diagnostic evaluation, thereby triggering a referral. The ISTH-BAT 
is an instrument to record both the presence and the severity of 
bleeding symptoms covering 14 important sites of bleeding in pa-
tients.7,8 It has been validated extensively in patients with suspected 
von Willebrand disease (VWD).9‒11 The diagnostic utility of the 
ISTH-BAT with regard to platelet function disorders is, however, still 
elusive.12 With respect to adult patients, it has never been studied 
within the appropriate target population, namely, consecutive pa-
tients referred for evaluation of a suspected bleeding disorder.
With the present study, we aimed to assess the diagnostic value 
of the ISTH-BAT of the International Society on Thrombosis and 
Haemostasis for platelet function disorders in a representative co-
hort of patients.
2  | METHODS
2.1 | Study design, setting, and population
We included all patients older than 18 years of age referred with 
a suspected bleeding disorder to a specialized outpatient clinic of 
Inselspital University Hospital in Bern, Switzerland, between January 
2012 and March 2017. Reasons for the referral were (a) a bleeding 
tendency, (b) a family history of bleeding disorders, or (c) abnormal 
laboratory test results. Inselspital Bern is a tertiary university hospi-
tal in Switzerland covering a region with 1.5 million inhabitants. The 
catchment area of the hospital is representative for Switzerland with 
regard to German-speaking and French-speaking residents, as well 
as patients living in either urban or rural areas. Inselspital University 
Hospital comprises the only specialized laboratory and its hemato-
logical outpatient clinic functions as a reference center for coagula-
tion disorders.
Clinical data were prospectively recorded using an established 
in-house questionnaire as well as the ISTH-BAT sheet in the elec-
tronic hospital database. Laboratory data were stored accordingly. 
Patient files were coded using an in-house identification system and 
data were retrieved by two investigators working in parallel (MA/
JK, MN). All patients signed informed consent forms and the ethics 
committee approved the study protocol (No. 02289).
2.2 | Evaluation of patients and determination of 
ISTH‐BAT
The evaluation of patients was done using a standardized protocol as 
proposed in previous recommendations.4,7,13‒15 Before consultation, 
patients completed a 13-item, in-house questionnaire assessing the 
presence and severity of bleeding at specific organs, including the 
skin, nose, oral cavity, gastrointestinal and urogenital systems, joints 
and muscles, bleeding in association with minor injuries, dental pro-
cedures, surgery, transfusion requirements, bleeding after ingestion 
of drugs known to affect hemostasis, and family history.16 During 
the consultation, trained resident physicians took detailed history 
using a standardized form and applied the ISTH-BAT.7,8 The scores 
were applied prior to laboratory testing and physicians were not 
aware of any laboratory test results. The ISTH-BAT scorings were 
challenged by a second experienced physician (attending). Patients 
were instructed to stop anticoagulant treatment, antiaggregant 
treatment, nonsteroidal antirheumatic drugs, and/or selective ser-
otonin reuptake inhibitors 10 days prior to consultation. Potential 
bleeding stigmata including petechia, hematomas, as well as signs 
of amyloidosis, telangiectasia, or joint hyperflexibility, were docu-
mented after a thorough physical examination.
2.3 | Handling of samples
To prevent preanalytical errors, a standardized protocol was im-
plemented for blood drawing and preparation of blood samples.17 
Blood was collected by standard venipuncture with a 21-gauge 
needle in EDTA tubes (Monovette; Sarstedt, Nümbrecht, Germany) 
for blood cell count; in 0.106-mol/L trisodium citrate (9:1, v/v) 
tubes (Monovette; Sarstedt) for standard coagulation testing and 
platelet flow cytometric assays; and buffered citrate (0.13 mol/L 
trisodium citrate, pH 5.5) (Monovette; Sarstedt) for platelet ag-
gregation studies. Samples were transported manually to the 
laboratory.
Essentials
• The utility of bleeding assessment tools regarding plate-
let function disorders is still elusive.
• We studied consecutive patients in a prospective cohort 
study in a tertiary hospital.
• Substantially higher scorings were observed in patients 
with platelet function disorders.
• Bleeding assessment tools might provide a useful 
screening tool.
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2.4 | Laboratory evaluation
Laboratory evaluation was done in a stepwise manner with the 
following initial tests conducted simultaneously: blood count with 
mean platelet volume, a blood smear analyzing platelet morphology, 
prothrombin time, activated partial thromboplastin time, thrombin 
time, fibrinogen concentration (Clauss's method); and coagulometric 
determination of factor II, factor V, factor VII, factor X, factor VIII, 
factor IX, factor XI, factor XIII, von Willebrand factor (VWF) anti-
gen, VWF ristocetin cofactor activity, α2-antiplasmin, and platelet 
function analyzer 100. Secondary tests included light transmission 
aggregometry (LTA) and platelet flow cytometry if the initial test re-
sults were normal. In selected cases, chromogenic factor VIII, VWF 
multimer analysis, and VWF factor VIII binding capacity were also 
performed. Lumiaggregometry and molecular diagnostics were con-
ducted only in a few cases. Determination of LTA and platelet flow 
cytometry are described later; all other laboratory tests are reported 
in detail in the Supplementary Material.18
2.5 | Determination of light transmission 
aggregometry and platelet flow cytometry
Light transmission aggregometry was done inline with current recom-
mendations5,19 and as previously described16 using the aggregome-
ter APACT® 4004V (LABiTec GmbH, Ahrensburg, Germany). Platelet 
aggregation was induced by increasing concentrations of adenosine 
diphosphate (ADP) (Sigma-Aldrich, St. Louis, MO; 4, 6, and 10 μmol/L 
for male patients and 3, 4, and 6 μmol/L for female patients); colla-
gen (HORM®; Nycomed, Linz, Austria) at 1.5, 3, and 4 μg/mL; arachi-
donic acid at 2 mmol/L (Bio Data/Medonic Servotec AG, Interlaken, 
Switzerland); and ristocetin at 1.5 and 0.5 mg/mL (Socochim SA, 
Lausanne, Switzerland). Platelet-rich plasma (PRP) was prepared 
(centrifuged at 150 g for 15 min) and platelet count was adjusted to 
250 × 109/L. Then, 200 μL of PRP prewarmed at 37°C for 1 min was 
added to the aggregometer cuvette and run for an additional minute 
to exclude spontaneous aggregation; 20 μL of the agonist was added 
and the response was recorded. If the response to one agonist was 
outside the limits of the normal range, the test was repeated. The 
LTA was performed 1 h after collection of venous blood samples 
from the patient and was completed within 2.5 h. The in-house ref-
erence values have been previously established.20 A sample from a 
healthy volunteer was analyzed as an internal control; LTA was not 
performed when the platelet count was <100 G/L.
Platelet flow cytometry was conducted as previously de-
scribed.16 Surface glycoproteins (GPs) were analyzed using antihu-
man antibodies: Ibα (CD42b-PE; Ibα; Dako), GPIIb/IIIa (CD41-FITC, 
Becton Dickinson; CD61-FITC, Becton Dickinson), baseline P-selec-
tin expression (CD62P-PE, Becton-Dickinson), and PAC-1 binding 
(PAC1-FITC, Becton Dickinson). FACSCanto® (Becton Dickinson, 
Heidelberg, Germany) flow cytometer was used. The dose re-
sponse of platelet reactivity was investigated with ADP (0.5, 5.0, 
and 50 μmol/L), convulxin (5, 50, and 500 ng/mL), and thrombin 
(0.05, 0.5, and 5 nmol/L) with anti-CD62P and PAC1. The surface 
expression of negatively charged phospholipids was investigated 
using Annexin V-FITC (Roche, Rotkreuz, Switzerland) after incuba-
tion with either Ionophore A 23187 or the combination of convulxin 
(500 ng/mL) and thrombin (5 nmol/L). To evaluate the content and 
secretion of dense granules, platelets were loaded with mepacrine 
(0.17 as well as 1.7 μmol/L) and analyzed with thrombin. The in-
house reference values had been previously established.16 As a con-
trol, a sample from a healthy volunteer was analyzed in parallel with 
each run. Flow cytometric analysis was repeated once with different 
control platelets to confirm the results.
2.6 | Definition of diagnoses
Bleeding disorders were diagnosed following current recommen-
dations. Type 1 VWD was diagnosed with repeatable (two times) 
VWF:GPIbM levels of 0.05 to 0.4 U/mL and VWF:Ag of 0.05 to 0.4 U/
mL, a VWF:GPIbM/VWF:Ag ratio of >0.7, a normal multimer pattern, 
and an appropriate bleeding history.21‒25 The threshold of 0.4 U/mL 
was chosen rather than a 0.3 in order to simplify treatment decisions 
in clinical practice.26 Type 2 VWD was diagnosed according to ISTH 
criteria.23 Low VWF was diagnosed in patients with VWF:GPIbM or 
VWF:Ag below 0.5 U/mL, not meeting the criteria mentioned, and 
associated with blood group O.14 Hemophilia and other single-factor 
deficiencies were diagnosed according to current definitions.27
Interpretation of LTA and flow cytometry was done according 
to previous recommendations and established in-house reference 
ranges 16 by three experienced individuals; discrepancies were re-
solved by discussion.3,4,6,28‒30 Lumiaggregometry was additionally 
considered if available (in a few patients only). We categorized PFD 
into “confirmed platelet function disorder” in cases with repeated ab-
normal LTA and/or flow cytometry measurements in the absence of 
other disorders and “possible platelet function disorder” if only one 
measurement was available or there were inconclusive results, or 
concomitant disorders were present. Patients were categorized into 
one of the following PFD subgroups: (a) Glanzmann's thrombasthenia, 
defined as a defect in GPIIb/IIIa associated with a severely diminished 
aggregation of all agonists except ristocetin, reduced expression 
of GPIIb/IIIa, and/or markedly reduced activation of PAC1-bind-
ing1,3,31,32; (b) Gi-like defects, defined as an accentuated deficiency in 
aggregation to the Gi-coupled receptor antagonists ADP and adren-
aline, associated with corresponding flow cytometry results1,3,32; (c) 
thromboxane A2 pathway defects, defined as an absent aggregation 
in response to arachidonic acid, and possibly associated with an 
impaired response to other agonists1,3,19,31,32; (d) dense granule se-
cretion defects, defined as a defect in storage and/or secretion of me-
pacrine1,3,16,31,32; (e) collagen receptor defects, defined as an isolated 
reduction in aggregation and secretion after stimulation with collagen 
and convulxin1,16,32; (f) α-granule disorders, defined as a reduced ex-
pression and/or secretion of P-selectin, associated with varying im-
paired aggregation after stimulation with collagen and epinephrine 
1,16; (g) decreased generation of procoagulant (COAT) platelets, de-
fined as an impaired binding of Annexin-V after incubation with con-
vulxin and thrombin16; (h) complex disorders, defined as defects in a 
     |  1107ADLER Et AL.
number of agonists (LTA) and/or several flow cytometry results that 
cannot be attributed to any of the disorders mentioned.
We defined a “bleeder of undefined cause” as a patient with an 
abnormal ISTH-BAT (male ≥4 points; female ≥6 points) if results of all 
other tests mentioned in the diagnostic evaluation were normal and 
no bleeding disorder was identified.33‒35 Patients who did not have 
hemostatic disorders but did have systemic disorders associated 
with bleeding symptoms (e.g. hereditary telangiectasia and throm-
bocytopenia) were categorized as having “systemic disorders.”
2.7 | Statistical analysis
Descriptive statistics were used to characterize the study population 
(numbers/percent or median/interquartile range as appropriate). 
To evaluate the ISTH-BAT ability to discriminate between patients 
with or without a demonstrable platelet defect on platelet function 
testing, a receiver-operating characteristic curve analysis was per-
formed and simple logistic regression was computed with the Stata 
14.2 statistics software package (StataCorp. 2014. Stata Statistical 
Software: Release 14 College Station, TX: StataCorp LP). Figures 
were created using Prism 6 (GraphPad Software, Inc., La Jolla, CA).
3  | RESULTS
3.1 | Patient characteristics
Between January 2012 and March 2017, 555 patients were referred 
with a suspected bleeding disorder and were included in the study 
cohort (Figure 1A). Patients were referred from general practition-
ers in 200 cases (36.0%), from gynecologists in 121 (21.8%), and 
from other medical specialists in 207 cases (37.2%). The reason for 
referral was a bleeding tendency in 453 cases (81.6%), abnormal co-
agulation tests in 35 cases (6.3%), family history in 42 cases (7.6%), 
and verification of a known hemostatic disorder (reevaluation) in 8 
cases (1.5%). The median age was 42.9 years (interquartile range 
[IQR] 28.0, 64.8) and 371 patients were female (66.9%). Of all pa-
tients, 55 were being treated with antiplatelet drugs (9.9%; stopped 
10 days before assessment) and 34 were receiving anticoagulant 
treatment (6.1%; predominantly vitamin K-antagonists). The ISTH-
BAT was abnormal in 153 patients referred for a bleeding tendency 
(35%) and in 156 patients referred for any reason (28.1%). Detailed 
patient characteristics are displayed in Table 1.
3.2 | Type of bleeding disorders
A bleeding disorder was diagnosed in 288 patients (51.9%; Figure 1; 
Table 1). The underlying type of bleeding disorder was a possible 
platelet function disorder in 64 cases (11.5%), confirmed platelet 
function disorder in 54 cases (9.7%), von Willebrand disease and low 
von Willebrand factor in 50 cases (9.1%), mild hemophilia in 5 cases 
(0.9%), deficiency of other coagulation factors in 7 cases (1.3%; in-
cluding 6 patients with factor XI deficiency and 1 patient with fac-
tor X deficiency), fibrinogen disorders in 6 cases (1.1%), disorders 
of fibrinolysis in 7 cases (1.3%; including 1 patient with α2-antiplas-
min deficiency, 3 patients with PAI1 deficiency, and 3 patients with 
F I G U R E  1   A, Flow of the patients. The clinical characteristics and laboratory data of all consecutive patients referred between January 
2012 and March 2017 to an outpatient unit of a university hospital with a suspected bleeding disorder were collected prospectively. The 
diagnostic evaluation was performed according to current guidelines and platelet function was tested using light transmission aggregometry 
as well as flow cytometry. B, Classification of patients according to diagnosis. FVII, factor VII; MBD, mild bleeding disorder; PFD, platelet 
function disorder; VWD, von Willebrand disease; VWF, von Willebrand factor
A B
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abnormal clot lysis time) anticoagulant treatment in 5 cases (0.9%), 
and a systemic disorder in 38 cases (6.9%).
3.3 | Subgroups of PFD
Of 118 patients with a possible PFD, a confirmed subgroup could be 
established in 54 patients (46%). In contrast, diagnostic evaluation was 
not conclusive in 64 patients (54%). Distributions of PFD subgroups 
according to these two diagnostic groups are shown in Table 2. Gi-like 
defects were found most frequently (32%), followed by complex disor-
ders (28%), and diminished procoagulant COAT platelets (8%).
3.4 | Results of ISTH‐BAT scorings according 
to diagnosis
The median value of the ISTH-BAT bleeding score in patients with-
out a bleeding disorder was 2 (IQR 1, 4). In contrast, the ISTH-BAT 
bleeding score was 4 (IQR 3, 7) in patients with a possible platelet 
function disorder and 7 (IQR, 5, 9) in patients with a confirmed plate-
let function disorder (Table 3; Figure 2). The score was 4 (IQR 2, 7) in 
patients with low VWF/VWD and 4 (IQR 1, 8) in patients with other 
coagulation disorders. Patients with systemic disorders associated 
with bleeding symptoms had a median score of 3 (IQR 1, 4).
3.5 | Predictive value of ISTH‐BAT
The ROC curve analysis demonstrated an area under the curve 
(AUC) of 0.75 (95% CI 0.70, 0.80; Figure 3). In male patients only, 
AUC was 0.77 (0.68, 0.86); in female patients only, AUC was 0.74 
(0.67, 0.80). At a threshold of 4 (males), sensitivity was 76.9% (95% 
CI 68.2, 84.2), and specificity was 62.4% (57.6, 67.0). At a threshold 
of 6 (females), sensitivity was 52.1% (42.7, 61.5), and specificity was 
86.1% (82.4, 89.2).
4  | DISCUSSION
In our cohort of consecutive patients assessed for a suspected bleed-
ing disorder in clinical practice, we identified 54 patients with a con-
firmed PFD (9.7%) and 64 patients with a possible PFD (11.5%). Results 
TA B L E  1   Characteristics of patients referred with a suspected bleeding disorder (n = 555; 2012-2017)
Characteristics
Numbers (%) or median (IQR) as appropriate
Missing data
No bleeding 
disorder
Possible platelet func‐
tion disordera
Confirmed platelet func‐
tion disordera
Other bleeding 
disorders
Patients 267 (48.0) 64 (11.5) 54 (9.7) 170 (30.6) 0
Age (y) 40.2 (27.3, 60.4) 49.3 (34.9, 63.9) 49.8 (33.5, 64.0) 44.3 (30.7, 61.7) 0
Sex
Female 186 (69.7) 52 (74.3) 32 (66.7) 101 (59.4) 0
Male 81 (30.3) 18 (25.7) 16 (33.3) 69 (40.6) 0
Reason for referral
Bleeding tendency 191 (75.5) 63 (98.4) 51 (94.4) 148 (88.6) 17
Abnormal coagulation 
test results
25 (9.9) 1 (1.6) 0 (0) 9 (5.4)
Family history 33 (13.0) 0 (0) 3 (5.6) 6 (3.6)
Reevaluation 4 (1.6) 0 (0) 0 (0) 4 (2.4)
Referring physician
General practitioner 90 (35.9) 22 (32.8) 20 (42.6) 68 (41.7) 27
Gynecologist 51 (20.3) 18 (26.9) 18 (38.3) 34 (20.9)
Other specialist 110 (43.8) 27 (40.3) 9 (19.2) 61 (37.4)
Antiaggregant treatment 23 (9.5) 11 (17.2) 3 (6.8) 17 (10.8) 47
Anticoagulant treatment 13 (4.9) 3 (4.3) 2 (4.2) 16 (9.4) 3
SSRI treatment 16 (6.0) 8 (11.4) 4 (8.3) 7 (4.1) 57
VWF:C 110 (82, 136) 101 (79, 136) 98 (79, 133) 93 (57, 134) 72
VWF activity 107 (81, 131) 99 (72, 126) 100 (75, 137) 84 (55, 126) 73
Platelet count 235 (200, 267) 256 (223, 307) 235 (186, 270) 227 (184, 273) 4
Abbreviations: IQR, interquartile range; SSRI, selective serotonin reuptake inhibitors; VWF:C, von Willebrand factor antigen.
aDiagnosis of a platelet function disorder was made using light transmission aggregometry and platelet flow cytometry. “Confirmed platelet function 
disorder” was defined as abnormal results in repeated light transmission aggregometry/flow cytometry measurements in the absence of other 
disorders, “possible platelet function disorder” as an abnormal result in one measurement available, inconclusive results or presence of concomitant 
disorder. 
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of ISTH-BAT were substantially higher in patients with possible and 
confirmed PFD compared to patients without a bleeding disorder. The 
predictive value of ISTH-BAT for the presence of PFD was good.
Our results are essentially in line with previous investigations 
conducted in different settings and using other study designs. In a 
subgroup of patients studied in a pediatric setting, the ISTH score 
was higher in 5 patients with a possible PFD (median 3) compared 
to patients without a bleeding disorder (median 1).30 Rashid and 
colleagues compared ISTH-BAT scorings between patients with 
suspected PFD and healthy volunteers in Pakistan and found a sta-
tistically significant difference (median 2 versus median 0).36 Lowe 
at al. studied 79 patients with excessive bleeding and 21 healthy 
volunteers and compared ISTH-BAT according to lumiaggregometry 
results (adenosine triphosphate release). The ISTH-BAT was signifi-
cantly higher in patients with abnormal ATP release compared to 
patients without (median 12 versus median 0 points).37 Perez et al 
calculated ISTH-BAT retrospectively in 61 patients with thrombo-
cytopenia and/or suspected PFD and found an association between 
abnormal ISTH-BAT and LTA results.38 Kaur and colleagues com-
pared ISTH-BAT scorings between 48 patients with Glanzmann's 
thrombasthenia or Bernard-Soulier syndrome and healthy controls 
and found a significant difference.39
In contrast to previous investigations, we studied the ISTH-BAT 
in a population that represents an unselected test target population 
and comprising all patients referred with a suspected bleeding dis-
order. Patients were consecutively included, preventing any selec-
tion bias. The number of patients studied was significantly higher 
than in previous investigations. We studied adult Caucasian patients 
and the evaluation was performed using a prespecified protocol 
including LTA as well as platelet flow cytometry. Our study does, 
however, have several limitations. First, the diagnostic evaluation 
was not finished appropriately in a number of patients resulting in 
a high proportion of patients with “suspected PFD.” Such patients 
were reluctant to appear several times in the outpatient unit and 
this has been encountered in clinical practice; we analyzed patients 
with suspected and confirmed PFD separately and a similar associ-
ation was observed in both groups. In our setting, tests beyond LTA 
and flow cytometry were available in some cases only (e.g. molecular 
diagnostics, ATP release, expanded LTA agonist panel, fluorescence 
TA B L E  2   Platelet function disorder subgroups
Disorder
Numbers (%)
Possible PFD 
(n = 64)
Confirmed 
PFD (n = 54)
Glanzmann's thrombastheniaa 0 4 (7.4)
Gi-like defectsb 20 (31.3) 18 (33.3)
TxA2 pathway defects 13 (20.3) 1 (1.9)
Collagen receptor defectsd 6 (9.4) 2 (3.7)
Dense granule disorderse 1 (1.6) 4 (7.4)
α-granule disordersf 1 (1.6) 5 (9.3)
Diminished procoagulant 
COAT plateletsg
3 (4.7) 7 (13.0)
Complex disordersh 20 (31.3) 13 (24.1)
Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphos-
phate; LTA. Light transmission aggregometry; PFD, platelet function 
disorder.
aPFD subgroups were defined as follows: Defect in GPIIb/IIIa associated 
with a severely diminished aggregation of all agonists except ristocetin, 
reduced expression of GPIIb/IIIa, and/or markedly reduced activation of 
PAC1-binding.1,3,31,32 
bAccentuated deficiency in aggregation to the Gi-coupled receptor 
antagonists ADP and adrenaline, associated with corresponding flow 
cytometry results.1,3,32 
cAbsent aggregation in response to arachidonic acid, and possibly asso-
ciated with an impaired response to other agonists.1,3,19,31,32 
dIsolated reduction in aggregation and secretion after stimulation with 
collagen and convulxin.1,16,32 
eDefect in storage and/or secretion of mepacrine.1,3,16,31,32 
fReduced expression and/or secretion of P-selectin, associated with 
varying impaired aggregation after stimulation with collagen and 
epinephrine.1,16 
gImpaired binding of Annexin-V after incubation with convulxin and 
thrombin.16 
hDefects in a number of agonists (LTA) and/or several flow cytometry re-
sults that cannot be attributed to any of the disorders mentioned above. 
TA B L E  3   ISTH-BAT scorings according to disease in patients referred with a suspected bleeding disorder (n = 555)
Disorder
Median score (IQR)
All patients Female patients Male patients
No bleeding disorder 2 (1, 3) 2 (1, 4) 2 (1, 3)
Possible platelet function disordera 4 (2, 7) 4 (2, 8) 4 (2, 6)
Confirmed platelet function disordera 7 (5, 9) 7 (5, 11) 6 (4, 8)
VWD/low VWFb 4 (2, 6) 4 (3, 6) 4 (2, 6)
Other disorderc 4 (3, 7) 6 (3, 8) 4 (2, 5)
Abbreviations: IQR, interquartile range; ISTH-BAT, International Society on Thrombosis and Haemostasis bleeding assessment tool; LTA, light trans-
mission aggregometry; VWD, von Willebrand disease; VWF, von Willebrand factor.
aDiagnosis of platelet function disorder was determined using light transmission aggregometry and platelet flow cytometry. “Confirmed platelet func-
tion disorder” was defined as abnormal results in repeated LTA/flow cytometry measurements in the absence of other disorders, “possible platelet 
function disorder” as abnormal result in one measurement available, inconclusive results or presence of concomitant disorders. 
bLow von Willebrand values associated with blood group 0; von Willebrand disease type 1 or type 2. 
cSystemic disorder associated with bleeding symptoms such as hereditary hemorrhagic telangiectasia, and thrombocytopenia. 
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microscopy). Thus, the particular molecular defect in many patients 
could not be found. However, our results are in line with a previous 
study using ATP-release37 and we do not anticipate that this intro-
duced any bias.
Our results suggest that ISTH-BAT is a useful screening tool 
in patients with suspected PFD. This is particularly supported by 
the high sensitivity. The ISTH-BAT might be applied for triggering 
a referral of patients with any bleeding tendency at all (including 
patients with PFD as well as VWD), or for triggering platelet func-
tion studies in patients with normal first-line test results. We do not 
believe that the ISTH-BAT is able to discriminate different types of 
mild bleeding disorders, e.g. PFD from VWD, and we do not believe 
that the ISTH-BAT might replace platelet function studies. Our study 
was not designed to demonstrate a respective difference and two 
observations suggest the opposite: (a) the specificity is moderate 
only, suggesting a relevant number of patients with abnormal ISTH-
BAT associated with other disorders than PFD and (b) a widely over-
lapping distribution of ISTH-BAT scorings among patients with PFD, 
VWD, and other disorders. This study must be replicated in other 
settings and employing alternative platelet function assays as well.
In conclusion, in a large study of patients referred for suspected 
bleeding disorders in clinical practice, patients with PFD had sub-
stantially higher ISTH-BAT scorings than patients without and the 
predictive value of ISTH-BAT was good. Our results suggest that 
ISTH is a useful screening tool for PFD in clinical practice.
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F I G U R E  2   Results of the ISTH-BAT according to the presence 
of a platelet function disorder. The ISTH-BAT was conducted in the 
evaluation of 555 consecutive patients referred with a suspected 
bleeding disorder. Diagnosis of platelet function disorder was made 
using light transmission aggregometry and platelet flow cytometry. 
“Confirmed platelet function disorder” was defined as abnormal 
results in repeated LTA/flow cytometry measurements in the 
absence of other disorders, “possible platelet function disorder” 
as abnormal result in one measurement available, inconclusive 
results or presence of concomitant disorders. The Mann-Whitney 
U test was applied. ISH-BAT, International Society on Thrombosis 
and Haemostasis bleeding assessment tool; LTA, light transmission 
aggregomtery
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F I G U R E  3   The receiver operating characteristic (ROC) curve 
of ISTH-BAT for the presence of confirmed platelet function 
disorder. Area under the ROC curve (AUC) was 0.75 (95% CI 0.70, 
0.80). At a threshold of 4, sensitivity was 76.9% (95% CI 68.2, 84.2) 
and specificity 62.4% (95% CI 57.6, 67.0). CI, confidence interval; 
IStH-BAT, International Society on Thrombosis and Haemostasis 
bleeding assessment tool  
[Correction added on May 31, 2019 after first online publication: 
In Figure 3, the percentages of sensitivity at a threshold of 4 have 
been amended from a previous version.]
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